GFG Capital LLC Makes New $35,000 Investment in Johnson & Johnson $JNJ

GFG Capital LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 229 shares of the company’s stock, valued at approximately $35,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on JNJ. HSBC boosted their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a research report on Friday. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $192.94.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.2%

JNJ opened at $190.66 on Friday. The stock has a market capitalization of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. The firm’s fifty day moving average price is $178.48 and its 200 day moving average price is $163.76. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $192.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.